These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38496692)

  • 21. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
    Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
    Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
    Peng X; Long X; Liu L; Zeng L; Yang H; Jiang W; Liao D; Li K; Wang J; Lizaso A; Mao X; Xu Q; Mansfield AS; Yang N; Zhang Y
    Eur J Cancer; 2020 Dec; 141():199-208. PubMed ID: 33171317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
    Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC.
    Cekay M; Arndt PF; Dumitrascu R; Savai R; Braeuninger A; Gattenloehner S; Steiner D; Roller F; Tello K; Hattar K; Seeger W; Sibelius U; Grimminger F; Eul B
    Front Oncol; 2023; 13():1182391. PubMed ID: 37655099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
    Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS
    Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.
    Han ZJ; Luo N; Li L; Liu ZL
    Ann Palliat Med; 2021 Jul; 10(7):8413-8419. PubMed ID: 33977727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
    Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report.
    Zhang Y; Shen JQ; Shao L; Chen Y; Lei L; Wang JL
    World J Clin Cases; 2021 Sep; 9(27):8220-8225. PubMed ID: 34621884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-small cell lung cancer cells with uncommon EGFR exon 19delins variants respond poorly to third-generation EGFR inhibitors.
    Lu Z; Yi Y; Wang L; Luo Y; Luo D; Xiong L; Shu Y; Luo H; Li J; Zhu W; Zeng Z; Liu A
    Transl Oncol; 2024 Jan; 39():101834. PubMed ID: 38006760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rechallenge of afatinib for
    Araki T; Kanda S; Komatsu M; Sonehara K; Tateishi K; Takada M; Kato A; Yamamoto M; Nishie K; Hama M; Agatsuma T; Kakizaki Y; Yoshiike F; Matsuo A; Chiaki T; Samizo K; Takagi Y; Yamaura M; Hanaoka M; Koizumi T
    Transl Lung Cancer Res; 2023 Jun; 12(6):1320-1327. PubMed ID: 37425417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two case reports of non-small cell lung cancer patients harboring acquired
    Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
    Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
    Okuma Y; Kubota K; Shimokawa M; Hashimoto K; Kawashima Y; Sakamoto T; Wakui H; Murakami S; Okishio K; Hayashihara K; Ohe Y;
    JAMA Oncol; 2024 Jan; 10(1):43-51. PubMed ID: 37991747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
    Sehgal K; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
    Oncologist; 2021 Apr; 26(4):281-287. PubMed ID: 32969527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osimertinib - effective treatment of NSCLC with activating
    Skrzypski M; Szymanowska-Narloch A; Dziadziuszko R
    Contemp Oncol (Pozn); 2017; 21(3):254-258. PubMed ID: 29180936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osimertinib in NSCLC With Atypical
    Ji J; Aredo JV; Piper-Vallillo A; Huppert L; Rotow JK; Husain H; Stewart S; Cobb R; Wakelee HA; Blakely CM; Wong ML; Gubens MA; Madani MH; Digumarthy SR; McCoach C; Piotrowska Z; Neal JW; Riess JW
    JTO Clin Res Rep; 2023 Mar; 4(3):100459. PubMed ID: 36879929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
    Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
    Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
    BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18-18 and EGFR amplification: A case report.
    Wang P; Fabre E; Martin A; Chouahnia K; Benabadji A; Matton L; Duchemann B
    Front Oncol; 2022; 12():918855. PubMed ID: 35957870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.